Pharmacodynamic profile of prostacyclin

https://doi.org/10.1016/S0002-9149(99)80377-4Get rights and content

Since the 1930s and the discovery by von Euler of a vasoactive, lipid-soluble substance that he erroneously assumed was generated by the prostate gland and therefore should be called “prostaglandin,” the family of prostaglandins has grown to some 90 substances. These lipid mediators are derived from arachidonic acid in the “arachidonic acid cascade.” In 1976, while looking for the enzyme that generates the unstable prostanoid thromboxane A2 from arachidonic acid, Moncada and Vane discovered prostaglandin I2 and renamed it “prostacyclin.” Prostacyclin is the main product of arachidonic acid in all vascular tissues tested to date and strongly vasodilates all vascular beds studied. It is also the most potent endogenous inhibitor of platelet aggregation yet discovered, both inhibiting aggregation and dispersing existing aggregates. It acts through activation of adenylate cyclase, leading to increased levels of cyclic adenosine monophosphate. It also appears to have a “cytoprotective” activity, as yet not completely understood. Its effects are short-lasting, disappearing within 30 minutes of cessation of infusion. A stable, freeze-dried preparation of prostacyclin (epoprostenol) is available for administration to humans, and several analogs with therapeutically desirable characteristics are currently being clinically tested and should become commercially available soon. Clinical application of prostacyclin is bedeviled by 2 characteristics: it is pharmacologically unstable, so care must be taken in its use, and the correct dosage regimens have not yet been established.

References (130)

  • MalmstenC et al.

    Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets

    Biochem Biophys Res Commun

    (1976)
  • HiggsEA et al.

    Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium

    Prostaglandins

    (1978)
  • WhittleBJR

    Role of prostaglandins in the defense of the gastric mucosa

    Brain Res Bull

    (1980)
  • OgletreeML et al.

    Studies on the protective effect of prostacyclin in acute myocardial ischemia

    Eur J Pharmacol

    (1979)
  • RibeiroLGT et al.

    Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality

    Am J Cardiol

    (1981)
  • OhlendorfR et al.

    Prevention of infarction-induced decrease in circulating platelet count by prostacyclin

    Thromb Res

    (1980)
  • BlackwellGJ et al.

    Prostacyclin prolongs viability of washed human platelets

    Biochim Biophys Acta

    (1982)
  • CarlsonRP et al.

    Effect of a glucocorticoid on prostaglandin production during simulated shock conditions in the perfused cat liver

    Biochem Pharmacol

    (1977)
  • GryglewskiRJ et al.

    Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig

    Prostaglandins

    (1975)
  • KorbutR et al.

    The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood

    Pharmacol Res Commun

    (1978)
  • NawrothPP et al.

    Prostacyclin production by perturbed bovine aortic endothelial cells in culture

    Blood

    (1984)
  • FuJ-Y et al.

    The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes

    J Biol Chem

    (1990)
  • O'SullivanMG et al.

    Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase

    J Biol Chem

    (1992)
  • MaierJAM et al.

    Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells

    J Biol Chem

    (1990)
  • ThiemermannC

    The role of arginine: nitric oxide pathway in circulatory shock

    Adv Pharmacol

    (1994)
  • GryglewskiRJ et al.

    Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

    Prostaglandins

    (1976)
  • MoncadaS et al.

    A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation

    Prostaglandins

    (1976)
  • SalmonJA et al.

    Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes

    Biochim Biophys Acta

    (1978)
  • Dembinska-KiecA et al.

    The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbit

    Prostaglandins

    (1977)
  • BeetensJR et al.

    Biphasic response of intimal prostacyclin production during the development of experimental atherosclerosis

    Prostaglandins

    (1986)
  • TremoliE et al.

    Increased platelet aggregability is associated with increased prostacyclin production by vessel walls in hypercholesterolemic rabbits

    Prostaglandins

    (1982)
  • SinzingerH et al.

    Prostacyclin generation in atherosclerotic arteries

    Lancet

    (1979)
  • MarksJ

    Critical appraisal of the therapeutic value of α-tocopherol

    Vitam Horn

    (1962)
  • HajjarDP

    Prostaglandins and cyclic nucleotides: modulators of arterial cholesterol metabolism

    Biochem Pharmacol

    (1985)
  • VaneJR

    Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

    Nature

    (1971)
  • Euler USvon

    Zur Kenntnis der pharmakologischen Wirkungen von Nativsekreten und Extrakten männlicher accessorischer Geschlectsdrüssen

    Arch Exp Pathol Pharmakol

    (1934)
  • BergströmS et al.

    Isolation of prostaglandin E1 from human seminal plasma

    J Biol Chem

    (1962)
  • MoncadaS et al.

    An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

    Nature

    (1976)
  • HambergM et al.

    Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

  • WekslerBB et al.

    Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells

  • MacIntyreDE et al.

    Localisation and stimulation of prostacyclin production in vascular cells

    Nature

    (1978)
  • MoncadaS et al.

    Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin

    Pharmacol Rev

    (1979)
  • WhittleBJR

    Gastro-intestinal Mucosal Blood Flow

  • AxelrodL et al.

    Prostacyclin production by isolated adipocytes

    Diabetes

    (1981)
  • UbatubaFB et al.

    The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time

    Thromb Haemost

    (1979)
  • BayerB-L et al.

    Anti-aggregatory effect of prostacyclin (PGI2) in vivo

    Br J Pharmacol

    (1979)
  • RosenblumWI et al.

    Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse

    Stroke

    (1979)
  • MinkesM et al.

    Cyclic adenosine 3′, 5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions

    J Clin Invest

    (1977)
  • MoncadaS et al.

    The prostacyclin/thromboxane balance and cardiovascular disease

  • VaneJR

    Clinical potential of prostacyclin

    Adv Prostaglandins Thromboxane, Leukot Res

    (1983)
  • Cited by (279)

    • Vasorelaxing effect of Garcinia cowa leaf extract in rat thoracic aorta and its underlying mechanisms

      2023, Journal of Traditional and Complementary Medicine
      Citation Excerpt :

      In addition to NO, a prostanoid, PGI2, is an important vasodilator derived from the endothelium, synthesized from arachidonic acid by enzymatic reaction of the cyclooxygenease (COX) pathway. PGI2 induces vascular smooth muscle relaxation by stimulating the adenylate cyclase to produce cyclic AMP that leads to a decrease in intracellular Ca2+, which, in turn, induces relaxation of vascular smooth muscle.24,25 The present finding shows that the vasorelaxing effect of G. cowa leaf extract was reduced when the thoracic aortic rings were pre-incubated with COX inhibitor indomethacin, suggesting that G. cowa leaf extract can stimulate prostanoid production and subsequently induce vasorelaxation.

    • Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity

      2023, Chest
      Citation Excerpt :

      Although there is an advancing appreciation that PAH is a heterogeneous disease with clinical differences within subgroups, still missing is a comprehensive catalogue of molecular and metabolic profiles underlying the clinical manifestations of PAH subgroup. Namely, plasma metabolomic profiles have been reported in PAH,29-32 and a few reports have examined circulating metabolites that may point to potential metabolic pathways altered in SSc (with or without PAH).33,34 These studies indicated that distinct metabolic signatures exist between PAH and healthy or disease control subjects.

    • Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS

      2020, Respiratory Medicine Case Reports
      Citation Excerpt :

      Prostacyclin is a naturally occurring prostaglandin which exerts its effects on vascular smooth muscle through a mechanism of action that is uniquely different from INO, and this probably accounts for its additional benefits in various pathologic conditions. It increases the concentration of cyclic adenosine monophosphate in vascular smooth muscle cells while INO produces cyclic guanosine monophosphate [18]. Prostacyclin also increases endogenous surfactant production, which is beneficial in ARDS because it may decrease the need for toxic ventilator settings by improving lung compliance [10].

    • Antihypertensive drugs and vasodilators

      2018, Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application
    View all citing articles on Scopus
    View full text